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 Abstract 
Longitudinally extensive transverse myelitis is characteristic but not pathognomonic for 
neuromyelitis optica spectrum disorders (NMOSD) and may mimic local tumors. In this 
retrospective study based on a cohort of 175 NMOSD patients we identified 7 cases who 
initially presented with a longitudinally extensive spinal cord lesion and underwent spinal 
cord biopsy due to MRI-suspected malignancies. Remarkably, routine neuropathology was 
inconclusive and did not guide the diagnostic process to anti-aquaporin-4 (AQP4)-
seropositive NMOSD. Serious postoperative complications occurred in 5/7 patients and 
persisted during follow-up in 2/7 patients (29%). Considering these sequelae, AQP4-antibody 
testing should be mandatory in patients with inconclusive longitudinally extensive spinal cord 
lesions prior to biopsy. 
 
 Introduction 
Neuromyelitis optica (NMO) is an inflammatory demyelinating autoimmune disease with the 
key features optic neuritis (ON) and longitudinally extensive transverse myelitis (LETM), 
characterized by a spinal cord MRI lesion ≥ 3 vertebral segments.1,2 However, LETM is not 
pathognomonic for NMO spectrum disorders (NMOSD),1 as longitudinally extensive spinal 
cord lesions (LESCL) can be observed with coexisting systemic autoimmune diseases, 
infections, vascular and metabolic disorders, and following irradiation.3-5 Moreover, 
intramedullary tumors or paraneoplastic myelopathies may present as LESCL and thus mimic 
NMO-associated LETM.3,4 Usually, clinical history and presentation, neuroimaging findings 
as well as cerebrospinal fluid (CSF) and serological tests guide the diagnostic work-up of 
NMOSD,6,7 particularly after the recent discovery of highly specific anti-aquaporin4-
antibodies (AQP4-Ab).8 However, in rare cases the identification of the underlying pathology 
is difficult, rendering spinal cord biopsy with potentially serious sequelae an ultimate means 
to rule out malignancies. Here, we retrospectively investigated the incidence and diagnostic 
value of spinal cord biopsy as well as the subsequent clinical outcome within a recently 
reported cohort of NMOSD patients.7 
 
Methods 
To identify NMOSD patients who underwent spinal cord biopsy we used the German 
Neuromyelitis Optica Study Group as previously described (www.nemos-net.de).9 At the time 
of analysis, 175 NMOSD cases as defined by Wingerchuk and colleagues (2007)1 had been 
captured.7 Patients  who underwent biopsy had been transferred for follow-up from 
neurosurgical and neurological hospitals to the Departments of Neurology in Düsseldorf or 
Berlin, Germany, and Hochegg, Austria, respectively. We were able to perform a 
neuropathological reevaluation in 4/7 cases, using the original biopsy specimen. The study 
was approved by the local ethics committees, and all patients gave written informed consent. 
  
Results 
We identified seven female NMOSD patients with a prior history of diagnostic spinal biopsy, 
6 of Caucasian, 1 of Afro-American origin, while the other patients of our cohort did not 
undergo spinal biopsy. None of the patients had a prior brain biopsy. The median age was 40 
years (range 24-52) at first clinical presentation and 43 years (range 29-57) at LETM/biopsy. 
LETM was the initial manifestation in 4 patients, 3 patients had experienced an inflammatory 
episode suggestive of NMOSD prior to biopsy (optic neuritis or rhombencephalitis; Table). 
Suspected diagnoses leading to biopsy 84 days after clinical onset (mean; range 8 days-10 
months) included “astrocytoma”, “atypical pen-like glioma”, “tumor of unknown etiology”, 
“spinal tumor” and “intramedullary tumor”. Spinal MRI showed non-homogeneous 
gadolinium enhancement (in 6/7 patients) with pronounced myelon swelling between the 
medulla oblongata and Th9 (range), extending >6 segments (mean, range 4-15; Figure). Brain 
MRI prior to biopsy was normal in 4/7 patients or revealed unspecific white matter lesions in 
3/7 cases. CSF analysis showed mild (5/7 patients) or moderate pleocytosis (2/7 patients) and 
isolated oligoclonal bands in one patient (Table). 
Remarkably, initial histopathological diagnoses did not suggest an NMO-related process but 
were reported as 1) “inflammatory destructive lesion”, 2) “glial tumor with desmoplastic and 
angiogenic compound of low malignancy”, 3) “angiodysgenetic necrotizing myelopathy Foix-
Alajouanine”, 4) “subacute necrosis, no tumor”, 5) “tumor-free spinal cord”, 6) “CNS tissue 
with severe reactive and resorptive changes, no neoplasia” and 7) “reactive CNS tissue with 
inflammation and resorptive changes” (Table).  
Reevaluation of four available biopsies was limited by the small sample size and numbers of 
sections. Demyelination was evident in all cases. Inflammation (CD3), extensive axonal 
damage (Bielschowsky silver impregnation) and hyalinized vessels were evident in 3/3 
biopsies. Perivascular complement depositions were not found (0/3; C9neo) and complement 
 within macrophages was evident in one case (1/3; C9neo). Only in one biopsy were 
eosinophilic granulocytes present. Both of the 2 cases in which GFAP and AQP4 could be 
stained showed astrocytic dystrophy and loss as well as loss of AQP4. Oligodendrocytes 
(NOGO-A or CNPase staining) were depleted in 2/2 biopsies (see supplemental Figure). 
All patients were AQP4-seropositive when tested after biopsy using cell-based assays. The 
final diagnoses were NMO (4/7) and NMO-related LETM (3/7) at an average of 68.4 months 
(range 0.5-160) after initial symptoms and 30.3 months (range 0.25-103.5) after biopsy 
(Table). Notably, 3 patients were biopsied before AQP4-Ab testing was routinely available 
(one in 1995, two in 2002).8 Testing was available but not performed before surgery in all 
other cases. Median EDSS prior to biopsy was 4.0 (range 2.5-8.0) and 8.0 (range 3.0-8.5) in 
the first few days thereafter, due to severe complications like CSF leakage, epidural 
hematoma (Figure), and postoperative spinal trauma in 5/7 patients. Biopsy-related 
deterioration persisted in 2/7 patients, with an elevated EDSS score of 7.5 (median; range 2.0-
8.5) at last follow-up (mean 86.6 months after spinal biopsy; range 20-218). 
 
Discussion 
Undoubtedly, CNS biopsy represents the ultimate diagnostic step for evaluation of an unclear 
tissue alteration such as a longitudinally extensive spinal cord lesion. NMO histopathology in 
general is characterized by inflammatory, often destructive, demyelinating lesions with 
perivascular immunoglobulin G and complement deposition, hyalinized vessels and 
eosinophilic granulocytes. An astrocytic pathology with AQP4 loss extending beyond the area 
of demyelination is typical and oligodendrocytes may be lost within lesions.10,11 However, 
invasive biopsy procedures may have adverse effects, particularly in the inflamed spinal cord. 
Moreover, in this case series, initial routine histopathology excluded tumors in 6/7 patients 
(Table), but did not lead to the correct diagnosis. Five patients experienced transient 
postoperative  complications shortly after biopsy, leading to persistent, severe paraparesis in 
 one patient  and permanent tetraparesis with wheelchair dependence in another. Obviously the 
proportion of severe post-operative complications was relatively high in our study, possibly 
due to the central localization of the spinal lesions as well as their inflammatory nature, 
leading to local hyperemia and thus an increased susceptibility to unintended bleeding events 
and edema. NMO-related LETM was only recognized after detection of NMO-IgG. Although 
histopathological reevaluation in 4 patients revealed some typical NMO features, a definite 
diagnosis was challenging despite familiarity with the AQP4 serostatus as certain 
neuropathological findings typical of NMO like perivascular depositions of activated 
complement were not detectable. This observation is in line with previous reports suggesting 
heterogeneity of NMO lesions according to lesion stage, biopsy site and the paucity of typical 
spinal specimen.10,11 
Our report confirms and extends a previous single case report,12 but has several limitations. 
The analysis is retrospective, and the patients were not recruited from a random population of 
patients with spinal lesions including confirmed cases of glioma but from a recently described 
cohort of NMOSD patients.7 Moreover, 3/7 patients were biopsied in 1995 and 2002 before 
the availability of NMO-IgG measuring.8 However, our findings emphasize the importance of 
NMO-IgG testing for LETM. Considering the possible adverse effects of biopsy procedures, 
testing for NMO-IgG is justified in patients with unclear spinal cord tumors. In light of the 
heterogeneity of available assays and the low prevalence of NMOSD, a detection method with 
sufficient sensitivity and specificity should be used.13 Biopsy of longitudinally extensive 
spinal lesions should be limited to cases in which other tests only provide inconclusive 
diagnostic findings.  
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Figure legends 
 
Figure: Pre- and postoperative spinal MRIs of patient #1. (A, B) Shown is a longitudinal 
and space-consuming transverse myelitis between vertebral segments Th2 and Th7 before 
diagnostic biopsy. The T2w image shows a particular swelling of the spinal lesion (A, white 
arrow heads) and the T1w image a low contrast Gadolinium enhancement (B, white arrows). 
Images (C) and (D) illustrate the postoperative state after spinal biopsy at level Th5. Epidural 
bleeding occurred at levels Th4-Th7 with ventral dislocation and compression of the myelon 
(open white arrows in T2w- (C) and STIRw- (D) images).  
 
Supplemental Figure: Histology of spinal NMO lesion of patient #6. Shown here is a 
destructive inflammatory demyelinating lesion with AQP4 loss. A small specimen is available 
for analysis from an eloquent lesion location within the spinal cord (A; HE). Higher 
magnification shows a destructive, loose-textured lesion with numerous macrophages (B; HE) 
and a T cell infiltrate (C; anti-CD3). Only few axons are preserved, underlining the destructive 
nature of the lesion (D; anti-NF200). Although the myelin is partially preserved (E; anti-PLP), 
higher magnification clearly shows myelin degradation products within macrophages, 
indicating active demyelination (F; anti-MBP; arrows indicate macrophages with myelin 
debris). Astrocytes appear partially dystrophic and partially depleted (G; anti-GFAP; arrow 
indicates dystrophic astrocyte), whereas AQP4 staining of astrocytes is completely lost (H; 
anti-AQP4). Macrophages show AQP4-positive degradation products within their cytoplasm 
(H; brown-colored macrophages). Scale bars: A: 500 μm; B-D: 100 µm; E: 200 μm; F+G: 50 
μm; H: 100 μm. 
 
 
Table: Cohort of patients with spinal biopsy due to presentation with longitudinally extending spinal cord lesions (LESCL). 
 Patient #1 Patient #2 Patient #3 Patient #4 Patient #5 Patient #6 Patient #7 
Age at onset, sex, 
origin 
52, female, 
Caucasian 
24, female, 
Caucasian 
45, female, 
Caucasian 
44, female, 
Caucasian 
47, female, 
Caucasian 
31, female, Afro-
American 
36, female, 
Caucasian 
Age at LESCL/biopsy 52 29 47 57 50 31 36 
Timespan first 
symptom to biopsy 
2 months 64 months 19 months 144 months  33 months 0.25 month (8 days) 4.5 months 
Timespan from LESCL 
onset to biopsy 
2 months 1.5 months 10 months 1 month 0.25 month (8 days) 0.25 month (8 days) 4.5 months 
ON or myelitis as 
initial event (date) 
Myelitis  
(01/2011) 
ON  
(10/1989) 
Myelitis  
(05/2001) 
Rhombencephalitis 
(1995) 
ON  
(10/2005) 
Myelitis 
(10/2011) 
Myelitis  
(11/2001) 
Optic neuritis  Never 2x left, 2x right 
before biopsy 
2x after biopsy (once 
bilateral, once left) 
Never 2x before biopsy 
(10/2005 + 12/2006) 
Never 1x after biopsy 
(10/2003) 
LESCL symptoms  Feet numbness, 
paraparesis (BMRC: 
5-/5), spinal ataxia, 
beltlike thoraco-
lumbar dysesthesia, 
sensory function loss 
below Th6  
Spastic paraparesis 
(BMRC: 4+/5), 
tetraataxia, voiding 
dysfunction, back 
pain, sensory 
function loss below 
Th5 
Gait disturbances, 
slight tetraparesis 
(BMRC: 4+/5), 
sensory function loss 
below C1 
Dysesthesia at 
occiput, right sided 
sensorimotor deficit 
Severe paraparesis, 
sensory function loss 
below Th3, voiding 
dysfunction 
Back pain, 
paraparesis, sensory 
function loss below 
Th4, voiding and 
defecation 
dysfunction 
Right sided foot and 
big toe extension 
palsy, back pain, gait 
instability 
Cerebral MRI at 
LESCL 
 
Multiple WML, Gd-; 
most likely 
microangiopathic 
Normal Normal Normal Unspecific WML Few unspecific 
gliotic changes 
Normal 
Spinal MRI of LESCL Th2-7, slight Gd+, 
longitudinally 
extensive centrally 
located lesion with 
cord swelling 
C2-6, focal Gd+, 
longitudinally 
extensive dorsally 
located lesion with 
cord swelling 
C1-7, focal Gd+, 
longitudinally 
extensive dorsally 
located lesion with 
mild cord swelling 
 Medulla oblongate-
C4/5, Gd-, 
longitudinally 
extensive centrally 
located lesion 
Th1-5, focalGd+, 
longitudinally 
extensive ventrally 
located lesion with 
cord swelling 
C7-Th6, focal Gd+, 
longitudinally 
extensive centrally 
located lesion with 
mild cord swelling 
C2-Th9, focal Gd+, 
longitudinally 
extensive centrally 
located lesion with 
cord swelling 
CSF at LESCL, OCB 
pattern 
4 cells/µl, Type 4 2 cells/µl, Type 1  6 cells/µl, Type 1 Minimal pleocytosis, 
Type1  
25 cells/µl, n.a. 51 cells/µl, Type 3 10 cells/µl, Type 1 
EDSS prior biopsy 2.5 3.5 2.5 4.0 5.5 7.5 8.0 
Suspected diagnosis 
prior to biopsy 
Astrocytoma, 
Ependymoma 
Atypical pen like 
glioma 
Tumor of unknown 
etiology 
Spinal tumor Spinal glioma 
(astrocytoma) 
Intramedullary tumor Intramedullary tumor 
Acute treatment of 
spinal cord lesion 
Dexamethasone, 
oral prednisolone, 
performed after 
spinal cord biopsy  
IV steroid pulse, 
transient good 
improvement 
Ceftriaxone, IV 
steroid pulse, IVIG, 
transient 
improvement 
IV steroid pulse, no 
improvement 
IV steroid pulse, 
transient minor 
improvement 
IV steroid pulse, 
performed after 
spinal cord biopsy 
IV steroid pulse, 
minor improvement 
Biopsy site (date) Th5 (03/2011) C3 (03/1995) C4 (12/2002) C2-6 (09/2007) Th3 (07/2008) Th4 (10/2011) Th2 (03/2002)  
 
Postoperative 
complications 
Epidural hematoma 
(requiring surgical 
revision), paraplegia 
None Slight increase of leg 
weakness and 
numbness 
CSF leakage (3 
surgical revisions), 
tetraparesis 
Paraplegia Paraplegia  None 
Initial histopathology Inflammatory, 
destructive CNS 
lesion 
 
Gliogenic tumor with 
desmoplastic 
angiogenic 
compound of low 
malignancy; DD 
atypical glioma 
Presumed 
angiodysgenetic 
necrotizing 
myelopathy Foix-
Alajouanine 
 
Subacute necrosis in 
clearence, 
definitively no tumor 
 
Tumor free spinal 
cord (no clear 
diagnosis possible) 
CNS tissue with 
severe reactive and 
resorptive changes. 
No neoplasia.  
Reactive CNS-tissue 
with inflammatory 
and resorptive 
changes 
AQP4-Ab tests (CBA) 
after biopsy 
Positive Positive  Positive Positive  Positive  Positive Positive 
 
Final diagnosis at last 
follow-up 
AQP4-Ab positive 
LETM 
AQP4-Ab positive 
NMO 
AQP4-Ab positive 
NMO 
AQP4-Abpositive 
LETM 
AQP4-Ab positive 
NMO 
AQP4-Ab positive 
LETM 
AQP4-Ab positive 
NMO 
EDSS at last follow-up 
/months after biopsy 
2.0/25 months 8.0/218 months 
 
8.5/121 months 7.5/69 months 8.0/23 months 4.0/20 months 
 
4.5/130 months 
Time from first 
symptom to final 
diagnosis 
2.5 months 144 months 30 months 160 months 34 months 0.5 month 108 months 
Time from biopsy to 
final diagnosis 
0.5 month 80 months 11 months 16 months 1 month 0.25 month 103.5 months 
Medication at last 
follow-up 
Rituximab  Rituximab  Rituximab, low dose 
steroids 
IVIG, low dose 
steroids 
Rituximab Rituximab Rituximab 
Abbreviations: AQP4-Ab: aquaporin4-antibody; BMRC: British Medical Research Council; C: cervical; CBA: cell based assay; CNS: central nervous system; CSF: cerebrospinal fluid; EDSS: 
Expanded Disability Status Scale; Gd: gadolinium; IV: intravenous; IVIG: intravenous imunoglobulins; LESCL: longitudinally extending spinal cord lesion; LETM: longitudinally extensive 
transverse myelitis; LFB: Luxol Fast Blue; MRI: magnetic resonance imaging; n.a.: not available; OCB: oligoclonal bands; ON: optic neuritis; Th: thoracic; WML: white matter lesions. 
Oligoclonal bands patterns (OCB-P): Pattern 1 = no OCBs in CSF and serum; pattern 2 = OCBs in CSF but not serum (intrathecal IgG synthesis); pattern 3 = OCBs in CSF but not serum 
(intrathecal IgG synthesis) plus additional identical OCBs in CSF and serum; pattern 4 = identical OCBs in CSF and serum (systemic immune reaction). 
 


